According to Gram Research analysis, a 2026 computational and experimental study found that melatonin reduced FOLH1 protein levels in prostate cancer cells and slowed tumor growth in mice at naturally occurring nighttime melatonin levels. However, this early-stage research hasn’t been tested in humans yet, and scientists emphasize that much more investigation is needed before melatonin could become a prostate cancer treatment.
Researchers used artificial intelligence and lab experiments to study a protein called FOLH1 that appears in many cancers, especially prostate cancer. They discovered that melatonin—a natural substance your body makes at night—might help slow down this cancer-promoting protein. In tests with cancer cells and mice, melatonin reduced the protein’s activity and slowed tumor growth. While these early results are promising, scientists emphasize that much more research is needed before melatonin could become a real treatment for people with prostate cancer.
Key Statistics
A 2026 research article published in PLoS Computational Biology found that melatonin suppressed FOLH1 expression in a concentration-dependent manner and restricted tumor growth in mouse models of prostate cancer at physiological circadian melatonin levels.
According to Gram Research analysis of the 2026 study, FOLH1 expression was significantly altered across 27 different cancer types, with prostate cancer showing particularly high levels of this cancer-promoting protein.
The 2026 integrated computational-experimental study demonstrated that melatonin not only reduced FOLH1 levels but also inhibited the invasive and migratory capacities of prostate cancer cells in laboratory assays.
The Quick Take
- What they studied: Whether melatonin, a natural sleep hormone, could reduce the activity of a cancer-promoting protein called FOLH1 that’s found in high levels in prostate cancer.
- Who participated: The study used cancer cells grown in laboratories and mice with human prostate cancer tumors. No human patients were involved in this early-stage research.
- Key finding: Melatonin reduced FOLH1 protein levels in cancer cells and slowed tumor growth in mice at levels similar to what your body naturally produces at night.
- What it means for you: This is very early research showing melatonin might be worth studying further for prostate cancer. It’s not a treatment yet, and people shouldn’t take melatonin supplements expecting cancer protection without talking to their doctor first.
The Research Details
Scientists used a two-step approach to find potential cancer treatments. First, they used artificial intelligence—specifically a computer program trained to recognize patterns—to search through thousands of known drugs to find ones that might interact with the FOLH1 protein. The AI identified melatonin as a promising candidate. Second, they tested melatonin in the laboratory using cancer cells and in living mice with prostate cancer tumors to see if it actually worked.
The researchers examined FOLH1 expression patterns across 27 different cancer types to understand how common this protein problem is. They also looked at how FOLH1 relates to immune cells in tumors, which is important because the immune system helps fight cancer.
This combination of computer prediction followed by real-world testing is called an ‘integrated computational-experimental framework’—basically, letting AI make educated guesses, then proving those guesses work in actual experiments.
This research approach matters because finding new cancer treatments is slow and expensive. Using AI to narrow down possibilities from thousands of drugs to just a few promising candidates saves time and money. Testing melatonin specifically matters because it’s a natural substance that people already use safely for sleep, making it potentially easier to develop as a treatment if it proves effective.
This study combines computational prediction with laboratory validation, which strengthens the findings. However, the research is still in early stages—it hasn’t been tested in human patients yet. The study was published in PLoS Computational Biology, a peer-reviewed journal, meaning other scientists reviewed the work before publication. The authors appropriately emphasize that more research is needed before any clinical applications.
What the Results Show
Melatonin successfully reduced FOLH1 protein levels in prostate cancer cells in a dose-dependent manner, meaning higher concentrations of melatonin produced stronger effects. The reduction happened at melatonin levels similar to what your body naturally produces during sleep, suggesting the effect might be biologically relevant.
In mice with human prostate cancer tumors, melatonin treatment restricted tumor growth compared to untreated mice. The treatment also reduced the cancer cells’ ability to invade surrounding tissue and migrate to other locations—two hallmarks of aggressive cancer.
The AI analysis revealed that FOLH1 expression patterns vary significantly across different cancer types, with prostate cancer showing particularly high levels. This suggests FOLH1 might be an important target for multiple cancers, not just prostate cancer.
The study found that FOLH1 expression correlates with immune cell infiltration in tumors in cancer-specific ways. This means different cancers show different relationships between FOLH1 levels and immune cell presence, suggesting FOLH1 might affect the immune system differently depending on cancer type. The researchers also demonstrated that melatonin’s effects were concentration-dependent, meaning the relationship between dose and effect was predictable and measurable.
Previous research has shown that FOLH1 (also called PSMA) is overexpressed in prostate cancer and is already being targeted by some experimental treatments. This study adds to that knowledge by systematically examining FOLH1 across many cancer types and by identifying melatonin as a potential modulator. The finding that melatonin might work through FOLH1 is novel and hasn’t been extensively studied before, making this research a new direction in prostate cancer research.
This study has important limitations. First, it only tested melatonin in cancer cells and mice, not in human patients. Results in mice don’t always translate to humans. Second, the study doesn’t fully explain the biological mechanism—exactly how melatonin reduces FOLH1 and stops cancer growth remains unclear. Third, the sample size for animal studies wasn’t specified in the abstract. Finally, the researchers acknowledge that further mechanistic validation is needed, meaning we need to understand the ‘why’ behind the results before considering clinical applications.
The Bottom Line
This research is too early-stage to recommend melatonin as a prostate cancer treatment. People with prostate cancer should continue following their doctor’s recommended treatments. However, this study provides a foundation for future research that might eventually lead to melatonin-based therapies. The confidence level is low at this stage—this is exploratory research, not proven treatment.
Prostate cancer researchers and oncologists should pay attention to these findings as a direction for future studies. Men with prostate cancer should be aware of this research but shouldn’t change their treatment plans based on it. The general public should understand that while melatonin is safe for sleep, taking it as a cancer treatment without medical supervision isn’t supported by current evidence.
This research is in the laboratory phase. If melatonin moves forward, typical drug development takes 10-15 years before reaching patients. The next steps would be more detailed mechanistic studies, then safety testing in humans, then efficacy testing in clinical trials. Don’t expect melatonin-based prostate cancer treatments to be available soon.
Frequently Asked Questions
Can melatonin supplements treat prostate cancer?
Not yet. A 2026 study showed melatonin reduced cancer growth in mice, but human testing hasn’t occurred. Talk to your doctor before taking melatonin supplements if you have prostate cancer, as it’s not an established treatment.
What is FOLH1 and why does it matter in cancer?
FOLH1 is a protein that appears in abnormally high levels in many cancers, especially prostate cancer. It helps cancer cells grow and spread. Researchers are studying ways to block it as a potential cancer treatment strategy.
How did researchers discover melatonin might help with prostate cancer?
Scientists used artificial intelligence to screen thousands of drugs for ones that might interact with FOLH1. The AI identified melatonin as a candidate, which researchers then tested in cancer cells and mice, confirming it reduced tumor growth.
When will melatonin be available as a prostate cancer treatment?
This is very early research. If melatonin advances, typical drug development takes 10-15 years. The next steps involve understanding how it works, then safety and effectiveness testing in humans before any potential clinical use.
Is it safe to take melatonin supplements now based on this research?
Melatonin is generally safe for sleep at recommended doses, but taking it specifically for cancer prevention or treatment without medical supervision isn’t supported by current evidence. Always consult your doctor before starting supplements.
Want to Apply This Research?
- Users interested in prostate cancer research could track their awareness of emerging treatments by logging when they read about new studies, noting the study type (lab, animal, or human), and the estimated timeline to clinical use.
- Users could set a reminder to discuss this research with their oncologist at their next appointment, bringing a summary of the study to facilitate an informed conversation about emerging treatment possibilities.
- Create a ‘Research Tracker’ feature where users can follow specific cancer research topics, receive notifications when new studies are published, and maintain a personal timeline of how research progresses from lab to clinical trials.
This article describes early-stage laboratory and animal research. Melatonin is not an approved treatment for prostate cancer and should not be used as a substitute for medical treatment. If you have prostate cancer or are at risk, consult with your oncologist or healthcare provider before making any changes to your treatment plan or starting supplements. This research has not been tested in human patients and requires significant additional validation before clinical applications.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.